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Summary.-A number of tests have been described which are thought to be capable
of identifying carcinogens without using the actual induction of cancer as an end-
point. This study compares the performance of 6 such tests on a selection of 120
organic chemicals. The tests studies were: (1) mutation of Salmonella typhimurium;
(2) cell transformation; (3) degranulation of endoplasmic reticulum; (4) sebaceous
gland suppression; (5) tetrazolium reduction and (6) subcutaneous implant. A
further 4 tests were examined briefly, but were not included in the complete evalua-
tion.
The chemicals were classified into carcinogens (58) and non-carcinogens (62) on
the basis of published experimental data, and into 1 of 4 broad chemical classes.
There was considerable variation between tests in their ability to predict carcino-
genicity, with the cell-transformation test and the bacterial-mutation test being the
most accurate (94% and93% accurate respectively). These 2 tests were considered to
be of general use in screening, since they were clearly more accurate than the others.
Statistical consideration of various combinations of these tests showed that the use
of cell transformation and bacterial mutation together, provide an advantage over the
use of either test alone. The inclusion of the other 4 tests in a screening battery
predictably resulted in a great increase in overall inaccuracy and loss of discrimina-
tion, even though the detection of carcinogens is improved. All the tests were shown
to generate both false positive and false negative results, a situation which may be
controlled by the use, where possible, of appropriate chemical-class controls, to
identify the test which is optimal for the class of chemical under test. Structural
analogy may have a part to play in the rapid detection of environmental carcinogens,
and some general guidelines for its use are given.
INFORMATION about the carcinogenic
activity of chemicals has been gathered
from epidemiological studies and animal
experimentation. Epidemiological studies
based on geographical variations in cancer
incidence have indicated thatmanyhuman
cancers are caused, mediated or modified
by environmental factors (Higginson,
1969; Boyland, 1969; Wynder and Ma-
buchi, 1972; Higginson and Muir, 1973;
Cairns, 1975). Although one of the factors
is thought to be the presence of naturally
occurring and man-made carcinogens in
the environment (Clayson, 1962; Hueper
and Conway, 1964; Boyland, 1969; Din-
man, 1974; Weisburger and Williams
1975) those human cancers which are
known to be caused by chemicals are few
in number. These cancers, which have
been associated with specific chemicals
have generally been limited to groups of
people in a particular industry or occupa-
tion and, in total, make up only a small
part of the cancer burden in man. Because
oftheretrospectivenatureofepidemiology,
a carcinogenic hazard cannot be antici-
pated. Furthermore, epidemiological
studies are expensive and time-consuming,
and the gathering of complete and stati-
stically analysable data is difficult.I. F. H. PURCHASE ET AL.
Many hundreds of other chemicals,
however, have been shown to be carcino-
genic in animals (WHO/IARC publica-
tions 1972-75) and are, therefore, poten-
tially carcinogenic to man. Carcinogenesis
studies in animals can be used at present
to identify potential human carcinogens,
but suffer from problems of interpretation
due to modifying factors such as diet,
variations in spontaneous and induced
tumour incidences, species, strain and sex
differences. Further disadvantages of ani-
mal testing are high costs, protracted
duration of such studies and the resultant
heavy demands on animals and laboratory
resources.
There are many thousands of environ-
mental and industrial chemicals and to
test every chemical for carcinogenic
activity in animals would obviously be
very expensive and impracticable within
the foreseeable future. It is for this reason
that attempts are being made to develop
short term tests with non-cancerous end
points to identify carcinogenic chemicals.
There is now a greater understanding of
some of the mechanisms involved in
chemical carcinogenesis from metabolic
and structure-activity correlation studies
(Clayson, 1962; Brookes, 1971; Hueper and
Conway, 1964; WHO/IARC, 1974; Miller,
1970; Miller and Miller, 1971a, b, 1972,
1974; Dinman, 1974; Arcos and Argus,
1974) but in no case is there unequivocal
knowledge of the molecular target critical
to the induction of cancer (Miller, 1970).
Tests having non-cancerous end-points
were often derived from observations on
the effects produced by carcinogens, and
were adapted to screen chemicals (Monte-
sano et al., 1976; Stoltz et al., 1974;
Brookes and de Serres, 1976; Bridges,
1976). Their chief advantages are rapidity,
low cost and simplicity of operation,
thereby enabling a large number of
chemicals to be tested.
The main disadvantage of any test with
a non-cancerous end-point is that the
significance of the test response with
regard to carcinogenicity must be carefullv
assessed. With the exception of the Ames'
test (McCann et al., 1975) no extensive
evaluation has been made of any of these
tests. Furthermore with the exception of a
few reviews (Stoltz et al., 1974; Brookes
and de Serres, 1976) no attempt has been
made to compare tests.
We consider that detailed examination
of the available tests (Stoltz et al., 1974;
Montesano et al., 1976; Brookes and de
Serres, 1976) for predicting carcinogenicity
was impracticable. Instead, several tests
were selected for evaluation, bearing in
mind the available expertise, facilities and
published confidence in the various test
procedures. The methods selected for
study were the following:
(1) Ames test. Salmonella typhimurium
plate-incoporation mutagenicity
assay (Ames et al., 1975).
(2) Cell transformation. Mammalian cell
transformation in culture (Styles,
1977).
(3) Rabin's test. Degranulation ofrough
endoplasmic reticulum from rat liver
(Williams and Rabin, 1971).
(4) Sebaceous-gland test. Mouse-seba-
ceous-gland suppression (Bock and
Mund, 1958),
(5) Tetrazolium-reduction test. Reduc-
tion oftetrazolium red by mouse skin
(Iversen and Evensen, 1962).
(6) Implant test. Tissue reaction to
subcutaneous implants in mice
(Westwood and Longstaff, unpub-
lished).
A further 4 tests were considered, but
after a brief evaluation were found to be
unsuitable (see Appendix VIII).
The 120 chemicals chosen for the valida-
tion study were selected from a variety of
structural and functional classes, and
consisted of 58 carcinogens and 62 non-
carcinogens. This paper reports the results
ofa comparative evaluation carried out on
a number ofshort-term tests purporting to
identify chemical carcinogens. The evalua-
tions were also aimed at comparing the
tests individually and in groups, in order
to arrive at the most useful combination.
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A preliminary report has already been
published (Purchase et al., 1976).
MATERIALS AND METHODS
Criteria used to classify substances tested for
carcinogenicity
Category of carcinogenicity.-Only 2 cate-
gories of carcinogenicity have been used,
namely carcinogenic or non-carcinogenic.
Compounds have been classified by an assess-
ment of the available scientific literature
wherever possible. The assessment criteria
were as follows:
(a) Any materials shown to produce
malignant tumours in any mammalian species
as a result of application to the skin, i.p. or
i.v. injection, or orally (including intra-
gastrically), have been regarded as carcino-
genic.
(b) Initiating and promoting agents have
been classified as carcinogens.
(c) Tumours arising in the urinary bladder
as a result ofbladder implantation techniques
have not been considered as meaningful.
(d) Tumours arising at the site of subcuta-
neous injection (i.e. as sarcomas) have been
ignored unless accompanied by the appear-
ance of tumours at other sites.
(e) Negative results after s.c. injection or
bladder implantation have been regarded as
significant, and were considered an indication
of non-careinogenesis.
(f) Where there is only an increase in the
incidence of common tumours in mice (e.g.
ofhepatomas or lung adenomas in susceptible
strains) the data have been ignored, unless
there have been concurrent appearances of
other tumours at different sites.
(g) Evidence based solely on the appear-
ance of benign tumours has been considered
insufficient for a positive classification.
(h) Compounds which were negative in
studies which have continued for the major
part of the animal's lifespan have been
classified as non-carcinogens. Where there is
no reason to suspect carcinogenicity (e.g.
natural products of mammalian systems) or
on theoretical grounds (e.g. by analogy with a
closely related chemical known to be positive)
then the compounds in question have been
classed as negative.
Chemical class.-The compounds used in
this study were selected to represent a wide
range ofcarcinogens and non-carcinogens and
have been somewhat arbitrarily sub-divided
into the 4 chemical classes shown below.
Where possible, structurally related carci-
nogen andnon-carcinogenpairswereincluded.
The compounds were coded, and each was
tested without operator knowledge of their
biological activity. The 4 main classes of
chemicals are:
(a) Polycyclics (P). The group comprises
polycyclic and heteropolycyclic aromatic
compounds containing at least 2 fused
aromatic rings. The group includes several
substituted nuclei, but polycyclics bearing
amino substituents have been excluded, as
their carcinogenic metabolic activation is
thought to be dominated by this substituent
rather than the aromatic nucleus per se.
(b) Alkylating Agents (Alk). A variety of
chemical classes are included in this group,
all of which are capable of direct interaction
with nucleophiles, giving alkylation products.
Several alkyl nitrosamines are included, as
they can give rise to alkylating species
following suitable metabolic conversion.
(c) Aromatic Amines (AA). This group
consists of various nuclei each substituted
with an aromatic amino (anilino) or sub-
stituted amino group, which in the case ofthe
active examples, dominates the carcinogenic
response. The 2 groups ofcarcinogens centred
on 4-aminobiphenyl and benzidine and the
closelyrelatednitrobiphenylsarealsoincluded
in this group.
(d) Miscellaneous (M). This group contains
compounds which do not obviously fit into
any ofthe above groups on either a structural
or a functional basis.
A list ofthese chemicals together with their
group classification is given in Table I. The
compounds were tested on only one occasion
in each of the tests, except where additional
results are mentioned. This was a deliberate
decision and does not reflect routine labora-
tory practice where experiments may be
repeated. Compounds which gave incorrect
results were not re-tested; for example, the
incorrect negative results on vinyl chloride,
which is reproducibly positive in the Ames
test when tested as a gas in this laboratory,
was not altered during the validation study.
The effect of testing on only one occasion
would tend to reduce the accuracy of the
tests. One consequence of this approach,
however, is that too much emphasis should
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not be placed on individual results reported
in Table I without repeating them.
Short-term testing procedures
Chemical-structure correlation.-Since the
carcinogenic activities of the compounds used
in this study were classified from a study of
published information, chemical-structure
correlation was not used. However, when
tests are in routine use, a knowledge of the
structure of the compound would enable
analogies to be drawn between the test
compound and known carcinogens and non-
carcinogens. This would have 2 purposes:
firstly, to act as a primary screen to select
those compounds most worthy of attention;
and secondly, as a means of monitoring the
results of rapid screening, which will always
have a predictive accuracy ofless than 100%.
One way in which chemical-structure correla-
tion may be used to predict carcinogenic
activity is given in Appendix I.
Bacterial mutation.-Compounds were
tested using 4 strains of Salmonella in an
assay medium containing rat liver post-
mitochondrial supernatant and cofactors
(S-9 mix) according to the method of Ames et
al. (1975). Details of the method are given
in Appendix II.
Mammalian-cell transformation in culture.-
A new technique was developed in which
Syrian hamster kidney cells (BHK 21/cl 13)
and either human diploid lung fibroblasts
(W1-38) or human liver derived cells (Chang)
were exposed to 5 different doses of the test
compounds in vitro in serum-free liquid
tissue-culture medium containing rat post-
mitochondrial supernatant and cofactors (S-9
mix: Ames et al., 1975) to aid in metabolism
of the test compound. Following incubation,
cells were centrifuged and the medium con-
taining the compound and microsomes dis-
carded. The cells were resuspended in growth
medium. To assess survivalfollowing exposure
an aliquot (10 Fd) containing about 1000 cells
was incubated in liquid medium and colonies
counted after 6-8 days. A dose-response
curve for survival was constructed and the
LC50 calculated. To the remaining cell
suspension was added molten agar to give a
concentration of 0.3% agar in medium,
which allowed the growth of transformed
colonies (Macpherson and Montagnier, 1964).
Colonies were counted after 3 weeks' incuba-
tion, a dose-response curve for transformation
constructed and the number of transformed
colonies at the LC50 calculated. A 2-5 times
increase in colony numbers over controls was
regarded as positive. Although this test is
referred to as cell transformation, growth in
semi-solid agar is only one of the accepted
criteria for cell transformation. Details of the
test method are given in Appendix III.
Degranulation of rat liver rough endoplasmic
reticulum.-The loss of ribosomes from
isolated rat liver endoplasmic reticulum
(RER) following incubation with carcinogens
in vitro, first described byWilliams and Rabin
(1971) has been quantitatively assayed by
radio-tracer techniques (Purchase and
Lefevre, 1975). A statistically significant
increase in degranulation of the RER by the
test compound, over negative controls was
taken to indicate a positive result. The
method is described in Appendix IV.
Tetrazolium reduction.-The test was based
on that described by Iversen and Evensen
(1962). Samples ofmouse skin which had been
exposed to the test compound in vivo, were
incubated in aqueous solutions oftetrazolium
red. Increases in in situ biological reduction
of the colourless tetrazolium compound to
the coloured formazan were measured spectro-
photometrically, and taken to indicate a
positive response for the test compound. The
method is given in detail in Appendix V.
Mouse-skin sebaceous-gland suppression.-
Bock and Mund (1958) have demonstrated
that the sebaceous glands of mouse skin are
sensitive to the topicalapplicationof carcino-
gens. Test chemicals were applied directly to
mouse skin, and those causing a statistically
significant depression ofthe ratio ofsebaceous
glands to hair follicles were taken to be
positive. Details of this test are given in
Appendix VI.
Subcutaneous implant.-A novel technique
has been developed (Longstaffand Westwood,
unpublished) based on the s.c. implantation in
groups of mice of Millipore-filter discs over-
laid with a gelatinous suspension of the test
compound. The tissue surrounding the im-
plant was examined histologically after the
3-month test period and the lesions scored on
an arbitrary scale. A positive result was
recorded when the group mean was signi-
ficantly increased. The method is described
in Appendix VII.
RESULTS
The results obtained for each compound
from the different tests in this study
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are given in Table I. Each compound in
the list is followed by its source, chemi-
cal class, carcinogenicity and reference
to animal studies. The remaining columns
show the results of each test. Detailed
tabulations of results from each test can
be found in the appropriate Appendix,
and the detailed results from the 8 (+,
-) pairs of compounds in the cell trans-
formation and bacterial mutation tests
are given in Fig. 3-6.
TableIIshowsthenumberofcompounds
correctly identified by each of the short-
term tests. The data are presented for
each chemical class and for all compounds.
Table III gives the percentage correct
predictions made by each test on the
complete group of 120 compounds and on
each chemical class. The figures in paren-
theses are corrected for equal numbers of
carcinogens and non-carcinogens in each
chemical class.
TABLE I. Summary ofShort-term Predictive Testsfor Carcinogenicity
Compound
Acridine
2-Acetylaminofluorene
4-Acetylaminofluorene
Aflatoxin B
4-Aminoazobenzene
2-Aminobiphenyl
4-Aminobiphenyl
2-Aminochrysene
6-Aminochrysene
3-Aminopyrene
2-Aminonaphthalene-1 -
sulphonic acid
Aniline
p-Anisidine
Anthracene
2-Aminoanthracene
Anthranilic acid
Anthraquinone
Anthrone
1,2-Benzanthracene
Benzanthrone
Benzidine
Benzimidazole
Benzoic acid
3,4-Benzpyrene
6-Benzoyl-2-naphthol
Biphenyl
Bis azo compound (7)
Bis(Chloromethyl)ether
N,N'-Bis(2-naphthyl)-p-
phenylenediamine
Butanesultone
Caffeine
Calmagite (1)
Camphor
Carbazole
Chlorambucil
Chloramine T
Cholesterol
a)
0
0
D, G
C
E
H
H
B
H
C, F
C
B
L
D
B
D
B
B
L
D
D
A
J
F
B
B, C
B
A
L
D
L
H
B
B
B
A
B
A
B
A--
.
P- 1
AA+ 79, 80
AA- 81
MA+ 2
AA+ 3
AA+ 4
AA+ 5, 6,7,8
AA+ 9
AA+ 9
AA+ 10
AA-
AA- 11, 12, 13
AA- -
P- 14,15
AA+ 16, 17
AA- 18
M- 19
M-
P-+ 20,21,17
M- 22
AA-f- 23
P-
M- _
PA+ 24, 25, 26
M- -
M- 19
M- 97
Alk+ 32
AA- 19
Alk+ 27
M- 28
M-
M- 29, 30
P-
Alk+ 31
M-
M- 33
. e o
-4-- Ca);
+
+
+
0
0
Ca
,.O
0
-
+
+
+
+2
+)
+ +
+
+
+ - _
+ Nt Nt4
- +
+
-+ + _
+
+ -
- _
+
+
±
+
+
+
++ +
+
+ +
_ +
+
±
+
+
+ -
+ -
+
Ca
-4
Nt(10)
+
++
Nt
Nt
+
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TABLE I.-contd.
Compound 0.
Colchicine B
Croton oil B
Cyanocobalamin (B12) B
Cycasin acetate (2) S
Cyclohexylamine B
Cyclophosphamide C
3,3'-Diaminobenzidine L
2,7-Diaminofluorene B
3,4,5,6-Dibenzacridine B, D
1,2,3,4-Dibenzanthracene B, C
3,4,9,10-Dibenzpyrene B, P
3,3'-Dichlorobenzidine L
2,4-Dichlorophenoxyacetate A
Dicyclohoxylamine L
D.D.T. (3) A
Dieldrin (4) D
Diethylnitrosamine R
Diethylstilboestrol B
3,3'-Dimethoxybenzidine A, B
4-Dimethylaminoazobenzene D
9,10-Dimethylanthracene B
p-Dimethylaminobenzaldehyde D
7,9-Dimethylbenzacridine B
7,10-Dimethylbenzacridine B, C
9,10-Dimethyl-1,2-benzanthracene B, D
1,1'-Dimethyl-4,4'-bipyridinium M
dichloride
3,3'-Dimethylbenzidine D
Dimethylcarbamoyl chloride D
Dimethylformamide A, B
Dimethylnitrosamine R
2,3-Dimethylquinoxaline L
Dinitrobenzene C, D
2,4-Dinitrofluorobenzene D
2,4-Dinitrophenol B, D
Dinitrosopentamethylene L
tetramine
_+~ ;Q a -
M- 20
M+ 37 +
M -
Alk+ 35 + +
M- 36, 37 - -
Alk+ 38 + +
AA- 16 +
AA+ 39 - +
P+ 42 +
P+ 43 + +
P+ 44,45 + +
AA+ 41, 46 + +
M- 19, 47 -
M- 36 -
M- 48,49,50,51 -
M- 52, 53 - -
Alk+ 54,55,56 + +
M+ 57, 58 - -
AA+ 40,41 + +
AA+ 59, 60 + +
P+ 61 + +
AA--
P+ + +
P+ + +
P+ 62, 63, 64 + +
M- 106, 107
AA+ 114
AlkA+ 65
M- 66, 67, 68
Alk+ 69, 70, 71
P-
M-
M+ 72
M- 73
M- 40
DL-Ethionine A, B, C Alk+ 75
1,1'-Ethylene-2,2'-bipyridinium M M- 74
dibromide
Ethylenethiourea L M+ 19, 76
Ethyl methanesulphonate C, F Alk+ 77, 78
Hexachlorocyclohexane A M- 48, 82
Hexamethylphosphoramide A MA+ 83
Hydrazine K MA+ 84
Hydrocortisone B M- -
Indole B P- 85, 86, 87, 88
Merchlorethamine (5) B, N Alk+ 31, 89, 90
20-Methylcholanthrene B, C, D P+ 91, 92, 93
Methylene bis(2-chloroaniline) L AA+ 46
2-Methylindole B, D P-
MNNG (6) C Alk+ 94, 95
3-Methyl-4-nitroquinoline-N-oxide T AA- 96
Mitomycin C B Alk+ -
Morgan's base B P+ 42
Naphthalene D P- 15
I-Naphthol D M_ 98
2-Naphthol D M- 98
A- A-
A- A-
A-_
A- A-
.° 'C
C : s
+ - - +
+' +
+ - + +
+ -F -F Nt -F
-F - - A-
A-
A-
A-
A- A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
Nt
+ - _
_ A- A-
A- - Nt
A- - Nt
A- A- A-A
-4-
A-
A-
A-A
A-
A- -
A-
A-
A-
A-
A-
A- -
A- -
- Nt
A- -
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TABLE I.-contd.
Compound
1-Naphthylamine
2-Naphthylamine
2-Naphthylamine-1,5-disulphonic
acid disodium salt
Nitrobenzene
2-Nitrobiphenyl
4-Nitrobiphenyl
2-Nitrofluorene
N-Nitrosodiphenylamine
N-Nitrosoephedrine
N-Nitrosofolic acid
4-Nitroquinoline-N-oxide
4-Nonylphenol/ethylene oxide
condensate
Orotic acid
Perylene
Phenobarbital
N-phenyl-2-naphthylamine
Propanesultone
,-Propiolactone
Resorcinol
Riboflavin
Safrole
3,3',5,5'-Tetramethylbenzidine
Toluene
Toluene-2,4-diisocyanate
2,4,5-Trichlorophenoxyacetate
Trimethylphosphate
Urethane
Vinyl chloride
C)
C
0
B
L
L
L
C, D
B, D
L
u
L
L
B
B, C
B
L
L
B, C
A
B
H
u
A
L
A
A
A, B
E
Ee C ;: O
AA- 99,41,13 - - - - - -
AA+ 100,41,13 + - + + + -
AA-
M-
AA+ 101
AA+ 101
AA+ 10
M- 19
Alk+ 102
Alk+ 102
AA+ 103
M-
M-
P-
M-
AA-
Alk+
Alk+
M-
M-
M+
AA-
M-
M-
M-
M-
M+
Alk+
105
108
48, 28
19, 104
109
110
111
112
113
115
19
116
117, 118 119
120, 121
+F +
+ +
± +
+ ±
+ +
+ +
_v -
+ ±
± +
-
+ ±
+
+
+
+
+
+
±
+
+
+
±
±
+
Nt
Nt
+ +
+
+
+
_ - ~+
_+ -
- - - ~Nt
_ - + +
+
(1) Calmagite: 2-hydroxy-1-(2-hydroxy-5-methylphenylazo) naphthalene-4-sulphonic acid.
(2) Cycasin (acetate): methyloxymethanol acetate.
(3) D.D.T.: 1,1,1-trichloro-2,2-bis(4-chlorophenyl)ethane.
(4) Dieldrin: 1,2,3,4,10,10-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-endo-1,4-exo-5,8-dimetha-
nonaphthalene.
(5) Merchlorethamine: bis(2-chloroethyl)methylamine hydrochloride.
(6) MNNG: N-methyl-N'-nitro-N-nitrosoguanidine.
(7) Bis azo compound: 2,2'-Bis[1-(3-octadecylaminopropylimino)ethyl]-2,2'-[3,3'-dichloro-4,4'-biphenyl-
ylene)bis(azo)]bis(acetanilide).
(8) Chemical class and carcinogenicity:
AA Arylamines and related compounds.
Alk Alkylating agents.
P Polycyclic aromatic hydrocarbons.
M Miscellaneous compounds.
+ Carcinogen.
- Non-carcinogen.
(9) In the results of the implant test, + + denotes presence of tumour at site of implant.
(10) Nt: not tested.
Source of chemicals
A. BDH Chemicals, Shaw Road, Speke, Liverpool.
B. Sigma (London) Chemical Co., Ltd, Norbiton Station Yard, Kingston upon Thames.
C. Koch-Light Laboratories, Colnbrook, Bucks.
D. Fluorochem Ltd (Fluka), Dinting Vale Trading Estate, Glossop, Derbys.
E. Air Products Ltd, Sharp Street, Worsley, Walkden, Lancs.
F. Phase Separations Ltd, Deeside Industrial Estate, Queensferry, Flints.
G. Ralph N. Emmanuel Ltd, 264 Water Road, Alperton, Middx.
H. Aldrich Chemicals, Old Brick Yard, New Road, Gillingham, Dorset.880 I. F. H. PURCHASE ET AL.
J. May and Baker, Dagenham, Essex.
K. Hopkin and Williams Ltd, The Laboratory Centre, Ducie Street, Manchester.
L. ICI Ltd, Organics Division, Hexagon House, Blackley, Manchester.
M. ICI Ltd, Plant Protection Division, Fernhurst, Hazelmere, Surrey.
N. The Boots Company Ltd, Nottingham.
P. K. & K. Ltd, Kodak Ltd, Kirkby, Liverpool.
R. Eastman Ltd, Kodak Ltd, Kirkby, Liverpool.
S. Schwartz Mann, Uniscience Ltd, Airfleet House, Sullivan Road, London.
T. Lancaster Synthesis Ltd, St Leonards House, St Leonardgate, Lancaster.
U. J. Ashby and D. Paton, ICI Central Toxicology Laboratory.
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FIG. 1.-The effect of variations in p, the
the prior probability that a compound is a
carcinogen (or % of carcinogen in the
samples being tested) on P the probability
that a compound producing a particular
test result is a carcinogen. Each curve
represents a particular test result: (a)
bacterial mutation and cell transformation
positive; (b) cell transformation positive;
(c) bacterial mutation positive; (d) bacterial
mutation negative and cell transformation
positive; (e) bacterial mutation positive
andcell transformation negative; (f) bacter-
ial mutation negative; (g) cell trans-
formation negative; (h) bacterial mutation
and cell transformation negative. The
curves are calculated from the formula:
p= pA
pA + (1 - p)B
A is the probability of obtaining the test
result with carcinogens, and B is the
probability ofobtaining the test result with
non-carcinogens. The values for A and B
were obtained from this study.
DISCUSSION
The 6 tests compared in this paper were
developed in several laboratories and
each has been previously validated to
different extents. The test which has been
most extensively used is that developed
by Ames and his colleagues, and results
from testing over 300 chemicals have
recently been reported (McCann et al.,
1975). This is the first comparative blind
study of several tests carried out in one
laboratory.
The results of a validation study of
this type will be affected by a variety of
factors, which include the choice and
classification of chemicals, the inherent
reproducibility of the test systems, and
the fact that these experiments were not
repeated.
The chemicals used in this study were
selected to represent a wide range of
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FIG. 2.-The effect of variations in p the
prior probability that a compound is a
carcinogen (% ofcarcinogens in the samples
being tested) on P, the probability that a
compound producing a particular test
result is a carcinogen. Curves d and dd for
the test result bacterial mutation negative
and cell transformation positive; e and ee
for bacterial mutation positive and cell
transformation negative. Curves d and e
as in Fig. 1. Curves dd and ee are the false-
positive results, calculatedfromtheformula
p _ (1-p)B
pA + (1 - p)B
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structures, and included many of the
organic chemicals which are carcinogens in
animals and most of those which are
known to be active in man, but inevitably
some classes of carcinogen are not repre-
sented. The effect of this selection on the
c
-
0
0
z
TA 1535
C
a
-
0
6 z
JJ9/ plate
results of the validation study are difficult
to estimate, and care should be taken
when extrapolating these predictivity
figures to chemicals of a new structural
type, as discussed later. The classification
of the chemicals as carcinogenic or
TA 1538
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FIG. 3b. -* 2,4-Diuuitrofluorobenzene; --- - 1,3-Dinitrobenzene.
non-carcinogenic was, in most cases, classification are 1-fluoro-2,4-dinitroben-
relatively easy. Nevertheless, some of the zene, croton oil and 3,3-diaminobenzidine.
criteria used are controversial. Thus, Since there were few compounds within
there may be disagreement with the this category the effect of any changes on
classification of DDT, phenobarbital and the overall results would be relatively
dieldrin, which only produce an increase in small.
hepatomas or pulmonary adenomas in
mice, as non-carcinogens. Other com- Accuracy of the tests
pounds which presented difficulties in A comparison of the performance of
TA 1535
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FIG. 3c.-* * 2-Naphthylamene; 0----0 1-Naphthylamine.
the tests for carcinogens and non-carcino-
gens in each chemical class is given in
Tables II and III. The percentages have
been calculated on the number of com-
pounds actually tested; but, because the
chemical classes had differing proportions
of carcinogens and non-carcinogens, the
data have been transformed for equal
numbers of carcinogens and non-carcino-
58
gens in each class for comparative pur-
poses.
Table VII is an abstract of the results
in Table I for structurally related carcino-
gen and non-carcinogen pairs, first re-
ported by Purchase et al. (1976). The
Ames test correctly distinguished the 8
pairs of compounds, whereas cell trans-
formation failed to identify 2-naphthyl-
887
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FIG. 3d.- * * Nitrosofolic acid; O ---- 0 Diphenylnitrosamine.
amine as a carcinogen. The dose-response
curves obtained for the pairs of com-
pounds using the 2 tests are shown in
Figs. 3-6. It can be seen that in the cell-
transformation test of 2-naphthylamine
the transformation frequency rose rapidly
at doses greater than the LC50. Subsequent
testing gave a positive result with 2-
naphthylamine suggesting that the fail-
ure of the test reported here was for
technical reasons.
Short-term tests will usually be con-
ducted on compounds with unknown
carcinogenic activity. It is important that
the tests should be accurate for detecting
both carcinogens and non-carcinogens as
well as having a high overall accuracy. A
tabulation of the percentage of positive
TA 1538
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and negative results for both carcinogens
and non-carcinogens for each test is
given in Table IV. The differences between
the percentage of positive results for
carcinogens and non-carcinogens is stati-
stically significant (x2, P < 0.05) for all
tests except the tetrazolium test, indica-
400
350
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- 250
:
Z 200
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4,
150-
0
100-
0
z
so.
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300
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. 100
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z
50
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2500
ting that 5 ofthe tests had some ability to
discriminate between carcinogens and
non-carcinogens. The ratio of positive
results for carcinogens and non-carcino-
gens is a measure of the discriminating
power. This ratio, and the ratio for nega-
tive results, are given in Table IV. It is
TA 1538
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FIG. 4a.-Mutagenic response of Salmonella typhimurium strains TA 1535, TA 1538, TA 100 and
TA 98 to carcinogenic and non-carcinogenic pairs of structurally related compounds. *
4-Nitroquinoline-N-oxide; 0----0 3-Methyl-4-nitroquinoline-N-oxide.
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only the cell transformation and bacterial-
mutation tests which combine a high
predictive accuracy with a low level of
false results (indicated by the high ratios
in Table IV). Although the observed
levels of accuracy varied for each test
between the 4 classes of compounds, there
was statistical evidence of real differences
in accuracy for only one of the tests
(x2, P < 0.05): the degranulation test.
(Predictive accuracy for carcinogens
varied from 950 to 33%0 and for
non-carcinogens 82% to 46%.)
Jndependence of test results
If the tests were not independent, i.e.
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FIG. 4c. * * 2-Acetylaminofluorene; O --- -0 4-Acetylaminofluorene.
they allhadthe samepositive, negativeand
false results, the use of more than one test
would be unhelpful, because each test
used in addition to the first one would
merely be duplicating the results. The 15
possible pairs from the 6 tests have been
considered for evidence of non-indepen-
dence, separately for carcinogens and
non-carcinogens. There was no such evi-
dence (X2 test) for non-carcinogens for
any pair of tests. For carcinogens,
however, there was statistical evidence of
non-independence for the tetrazolium and
implant results. For these 2 tests the pro-
portion ofcompoundsrecorded asnegative
bythefirsttest washigherforthosenegative
in the second test thanforthosepositivein
the second test. This general low level of
TA 1538
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FIG. 4d. * * 9,10-Dimethylanthracene; O----0 Anthracene.
dependence suggests that it might be appears at first sight to provide consider-
worthwhile using a battery of tests for able advantages, particularly if the objec-
unknown compounds. tive is to increase the probability of
detecting all carcinogens. In using results A test battery from more than one test, the interpreta-
The idea of using a battery of tests tion is relatively easy if all tests agree.
892SIX TESTS FOR CARCINOGENICITY
% survivors
transformants
per106
survivors
pg/ml
FIG. 5a.-Survival curves in liquid culture
and frequency of transformation as ass-
essed by colony formation in semi-solid
agar of BHK 21 cells after dosing with
carcinogenic and non-carcinogenic pairs
of structurally related compounds.
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FIG. 6a.-Survival curves in liquid culture
and frequency of transformation as ass-
essedby colonyformation insemi-solid agar
of BHK 21 cells after dosing with carcino-
genic and non-carcinogenic pairs of struc-
turally related compounds. * 0
Dimethylcarbamoyl chloride; A- A
Dimethylformamide.
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TABLE III.-Percentage Accurate Predictions ofShort-term Tests
0/ Accurate predictions
Class of compound
Polycyclic
Carcinogens
Non-carcinogens
Arylamine
Carcinogens
Non-carcinogens
Alkylating agent
Carcinogens
Non-carcinogens
Miscellaneous
Carcinogens
Non-carcinogens
Total of all classes
Carcinogens
Non-carcinogens
Sebaceous-
Bacterial Cell trans- Degranula- gland
mutation formation tion suppression
95 95 65 90
100 91 73 100
89 100 55 78
94 97 76 62
95 95 95 55
92 100 46 75
83 94 61 67
83 94 61 67
94
89
95
93 (92)
91 (96)
94 (96)
92
78
95
94 (93)
91 (90)
97 (97)
73
33
82
71 (64)
71 (65)
71 (62)
57
55
57
65 (70)
67 (69)
64 (71)
In parentheses, corrected for equal numbers of carcinogens and non-carcinogens in each chemical class.
TABLE IV.-Percentage of Positive or Negative Results Obtained with Each Testfor Both
Carcinogens and Non-carcinogens
Test
Cell transformation
Bacterial mutation
Implant
Degranulation
Sebaceous gland
Tetrazolium
Positive results (0) Negative results (%)
Non- Non-
Carcinogens carcinogens Ratio Carcinogens carcinogens Ratio
91 3 30 9 97 11
91 6 15 9 94 10
37 5 7 4 63 95 1-5
71 29 2 4 29 71 2-4
67 36 1.9 33 66 2-0
40 27 1-5 60 73 1-2
TABLE V.-Performance ofShort-term Tests, Alone or in Combinations
Tests
CT
CM
Deg
SI
SG
TR
CT+BM
CT+BM+Deg
CT+BM+SI
CT+BM+Deg+SI
CT+BM+Deg+SG
CT+BM+SI+SG
CT+BM+Deg+SI+SG
CT+BM+Deg+SG+TR
CT+BM+SI+TR
All 6 tests
% of carcinogens which
would be +ve in at
least one test
91
91
71
37
67
40
99-19
99- 77
99 - 49
99-85
99 - 92
99-83
99 95
99- 95
99-90
99 - 97
of non-carcinogens
which would be +ve in
at least one test
3
6
29
5
36
27
8-8
35 -3
13-4
38-5
58-6
44-6
60-6
69-8
59-5
71 -33
* CT= cell transformation, BM = bacterial mutation, Deg = degranulation. SI = subcutaneous implants,
SG = sebaceous gland, TR = tetrazolium reduction.
NB:
1. Based on the results obtained in this study and assumptions stated in the discussion.
2. The number of decimal places does not represent the likely accuracy ofthese figures but demonstrates
the likely size of the differences between the examples given.
Tetrazolium
reduction
50
45
55
56
40
83
39
39
67
33
74
57 (51)
40 (40)
73 (71)
Implant
88
75
100
60
39
92
25
25
81
22
95
68 (59)
37 (23)
95 (95)1. F. H. PURCHASE ET AL.
TABLE VI. (IConpounds which Produced Different or False Results in the Cell Trancs-
formation and Bacterial IMutation Tests
Cell
transformation
Animal
carcinogenicity
,3,3'- I)iammnii obenlzidinie
1 -Naphthol
Perylene
Trimethylphosphate
2-Naphthylaminle
Diethylstilboestrol
Vrinyl chloridle
6-Benzoyl-2-naphthol
Hydrocortisone
Crotoni oil
2,7-Diaminofluorene,
3,4,53,6-Dibenzacrldine
Dimethylnitrosamine
DL-Ethionine
4-
-t
TABLE VII. Response of the 6 A'.hort-terrm Tests to 8 Carcinogen/Non-carcinoyen Pairs
Test compounild
4-Nitroquinoline-N-oxide
3-Aethyl-4-nitroqtinoliiie-
N-oxide
Betnzi(dine
3,3',5,5'-Tetramnethryl-
benizidine
2-Acetylaminofluorenie
4-Acet,ylaminofluiorene
9,10-Dimethylanthracene
Anthracene
Dimeth lcarbamoyl
chloride
Dimethylformami(le
1-Fluoro-2,4-dinitrobenzene
1,3-Dinitrobenzen
2-Naphthylamine
1-N'aphthylamine
Nitrosofolic aci(l
Diphenylnitrosamine
Number of pairs correctly
i(lentifie(1
* Not teste(l.
Subcuta- Sebaceous-
Ames Cell trans- Rabin's taneous gland
test foirmation test implants suppression
-I
Tetra-
zolium
reduction
Animal
carcino-
genicity
+v
tF
+-
-7 +
8 7 '4 a :3
In some cases, hiowever, the tests will not
all agree (see Table VI). When the tests
disagree, and no information is available
about the relative performance of the
test with that chemical class, it is likely
that a positive result in any test will be
considered to indicate that the compound
is a carcinogen. This process is likely to
increase the number of false-positive
results. The performance of the 6 tests
used for this study in various combinations
is given in Table V. As one would expect,
the ability to detect carcinogens (the
percentage of carcinogens giving a positive
result in at least one test) increases as
additional tests are used, but the advan-
tage obtained is not great when tests
in addition to cell transformation and
bacterial mutation are used. The
number of false positives (the percentage
non-carcinogens which are positive in at
least one test) also increases as the
number of tests increases. Using cell
transformation and bacterial mutation,
896
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the 2 "best" tests, thefalse positive results
increase from 3% or 6% respectively to
9%. When all 6 tests are used, 44/62 non-
carcinogens (71%) were positive in at
leastonetest. Abalanceis clearlynecessary
between the ability of the tests to detect
all carcinogens and the proportion of
false positives produced. On the basis of
the figures given in Table V, the combina-
tion of cell transformation and bacterial
mutation gives some advantage over the
use of one test alone.
The use of the 2 'best' tests
It is noteworthy that the combination
of the cell transformation and bacterial
mutation tests on the 120 compounds
detected all but 2 of 58 carcinogens, and
gave a positive result for only 6 of the 62
non-carcinogens. The relative importance
of these "false" positive and "false"
negative results when testing groups of
compounds will vary according totheratio
of carcinogens to non-carcinogens in the
group of compounds being tested. This
effect, based on a hypothetical test that
was 90% accurate for both carcinogens
and non-carcinogens, was described in our
preliminary report (Purchase et al., 1976).
Using the results obtained in this study,
and again making a number of assump-
tions which are stated later in this
discussion, Fig. 1 and2havebeenobtained.
Fig. 2 demonstrates the effect of varying
the proportion of carcinogens in the com-
pounds tested on the probability that a
compound which is positive in the bac-
terial mutation or cell transformation
test is a carcinogen. Two lines are drawn
in Fig. 1; one for the proportion of
carcinogens in the compounds judged as
positive and the other for the proportion
of non-carcinogens in these compounds
where the cell transformation is positive
and the bacterial mutation is negative.
(The 2 proportions must obviously sum
to one.) The lines for the alternative
result, namely cell transformation nega-
tive and bacterial mutation positive, are
very similar and have not been presented
in Fig. 2.
It can be seen from Fig. 1 that the use
of a combination of the 2 tests results in
a more confidentprediction ofthe carcino-
genicity of the compound when they
agree than if a single test had been used.
However, if the 2 tests disagree, little
further information is gained about the
potential carcinogenicity of the com-
pound.
If, for a given group of compounds to
be tested, an estimate of the proportion
of carcinogens is available, the proportion
of carcinogens with a given result can be
read from figures likeFig. 1. Alternatively,
study of the chemical structure of a
compound may enable us to make an
estimate of the probability of it being a
carcinogen, which is equivalent to esti-
mating the proportion of carcinogens in
that class of compounds.
The calculations on which the graphs
(Fig. 1 and 2) are based make certain
assumptions. These are: (a) that the 120
compounds used in this study are repre-
sentative of the compounds to be tested;
(b) that the results of the cell-transforma-
tion and bacterial-mutation tests are
independent; (c) that the tests have the
same degree of reproducibility in this
study as they will when used in future
and (d) that the classification of the 120
compounds into carcinogens and non-
carcinogens is correct.
In a future situation, a number of these
assumptions may not be valid; e.g. it is
unlikely that the 120 compounds used are
representative of all groups of compounds
to be tested in future and recent evidence
(Huberman et al., 1976) suggests that
cell transformation occurs as a result of a
mutational event which may be similar to
the reverse mutation in Salmonella. It
would'be advantageous to gather informa-
tion about the carcinogenicity and short-
term results of structurally related com-
pounds when testing a new compound;
to do so would alter the first assumption
above in favour of a more accurate result.
This theme is developed further in
Appendix I. The preceding discussion
considers the application of tests to large
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numbers of compounds, and the conse-
quences in terms of accuracy of prediction.
When these tests are used in practice,
however, results will have to be assessed
on a single compound or a group of
compounds within a chemical class. A
different set of considerations then has to
be taken into account.
The practical use of short-term tests
Short-term tests do not have cancer
induction as their end-point; rather they
each have some parameter which will
vary with the carcinogenicity or non-
carcinogenicity of the test compound.
Those already using, or advocating the
use of short-term tests to detect potential
chemical carcinogens should be aware of
the constraints under which such tests
operate.
The first constraint is that the test
parameters should not be given a status
greater than that of an arbitrary response,
irrespective of how biologically significant
any onetestmight appeartobewithrespect
to the theories ofthe chemical induction of
cancer (Boveri, 1914; Bauer, 1928; Bur-
dette, 1955; Brookes and Lawley, 1964;
Miller and Miller, 1971a, b; Ames et al.,
1973). The second constraint is that,
however many generalized data might be
generated to support the predictive accu-
racy of a given test (McCann et al., 1975;
Purchase et al., 1976; Bartsch et al., 1976)
this accuracy should not be assumed to
apply uniformly to compounds of every
chemical class. Therefore, any test should
be assessed by the correlation between
the results from this test and the known
in vivo carcinogenicity within the class of
compound being studied. It follows that a
single test may not be sufficient to cover
all classes of compounds, and it may be
necessary to evaluate potential carcino-
genicity within a given group of com-
pounds with a test other than that which
is generally used. The accuracy of a
short-term test for carcinogenicity has
been defined in this study as the per-
centage of carcinogens whiclh are positive
in the test. The Ames and cell-trans-
formation tests are able to identify more
than 90% of carcinogens, and on the
basis of this and other work the Ames
test is the most satisfactory established
test. However, relatively little attention
has been given to the converse problem of
how many compounds shown to be
positive in a short-term test are, in fact,
carcinogens. On the basis of the high-
predictivity figures mentioned above, one
would expect a high proportion of com-
pounds shownto bepositiveinthe Ames or
cell transformation tests to be carcinogens.
If this is so, the tests will be extremely
useful in predicting carcinogenicity,
irrespective of any other biological signi-
ficance ofthe positive result. Nevertheless,
attention should be given to the biological
significance, apart from carcinogenicity, of
a positive result in a test. This is particu-
larly so if the percentage of carcinogenic
compounds shown to be positive in the
test is relatively low. A positive result in
the Ames test indicates that a chemical
has induced genetic change, presumably
by interaction with DNA. Irrespective of
how well the Ames test results correlate
with carcinogenicity, the potential muta-
genicity of a compound shown to be
positive must be considered, and any
correlation between positive results in the
Ames test and mammalian mutagenicity
will need to be established independently.
The significance of a positive result in the
cell-transformation assay in terms of
biological phenomena other than carcino-
genicity is not so obvious, although cell
transformation too may be a mutational
event (Huberman et al., 1976). The
suitability of cell transformation as an
indicator of mammalian mutagenicity will
also need to be established. With the
sebaceous-gland, degranulation, sub-
cutaneous-implant and tetrazolium-reduc-
tion tests the significance of a positive
result in terms other than carcinogenicity
is not immediately apparent.
Although the previously published data
for the Ames test and the data generated
by this study for both the Ames and cell-
transformation tests, indicate that both
898899 SIX TESTS FOR CARCINOGENICITY
TABLE VIII.
Compound
H2N NH2
(I)
Cl Cl
H2N NH2
CH3 CH3
H2N NH2
CH30 OCH3
H2N NH2
CH3 CH3
H2N X NH2
CH3 CH3
(II)
Ames test Cell transformation
+ +
+ +
+ +
+
are reliable and highly predictive carcino-
genicity tests, the following examples
illustrate the difficulties which can be
met with when these or similar tests are
used for routine screening.
Table VIII shows the results obtained
in this study using these 2 tests with
derivatives of benzidine. The results
indicate that both test systems are able to
identify benzidine (I) and its carcino-
genic analogues as mutagens or trans-
formingagents,whilstfindingastructurally
related, but non-carcinogenic analogue
such as 3,3'5,5'-tetramethylbenzidine (II)
negative.
This test-response profile means that
confidence can be placed in the findings of
either of these test systems for previously
unevaluated derivatives of benzidine.
Furthermore, when testing such deriva-
tives with either of these tests, their
+
Anjinal
carcinogenicity
+-
+
+
continuing ability to discriminate between
carcinogens and non-carcinogens of this
class can be monitored by using benzidine
and 3,3'5,5'-tetramethylbenzidine as the
chemical class control pair (CCCP). This
practice would rapidly reveal any critical
changes in the test system, which may
have unknowingly occurred since the
initial exploratory study was carried out.
For example, it has been demonstrated
(Oesch et al., 1976) that a test response
can be critically manipulated by varia-
tions in a single enzyme in the S9 mix.
The concept that a test should be capable
of correctly identifying the appropriate
CCCP before analogues are evaluated
is a useful method of discerning false
results. For example, hydrazine (III),
hexamethylphosphoramide (IV), safrole
(V), urethane (VI) and diethylstilboestrol
(DES) (VII) have been associated withI. F. H. PURCHASE ET AL.
NH2-NH2 [[CH32N+-PO
(III) (IV)
H2N-CO,Et
(VI)
0
0
CH2-CH=CH2
(V)
HO Et
Et OH
(VII)
induction of tumours in rodents. Further-
more, each of these compounds can be
associated with a number of structural
analogues, any one of which might also be
carcinogenic and would, therefore, be
worthy of evaluation in an in vitro test.
However, asthere isnonegative compound
to form the CCCP before these structural
analogues are tested, it is important to
first study the response of the chosen test
tothereference carcinogen. Intheexamples
cited above each has been tested in the
Ames test and each gives a negative (as
in the case of DES) or erratic response.
Therefore, in any situation where an
erratic response is obtained the ability of
the test to identify the reference carcino-
gen should be demonstrated in each
experiment. Onlyundersuchcircumstances
can negative results be used to dis-
soeiate analogues from the in vivo carcino-
genicity of the parent carcinogen. There
is, consequently, a hidden danger in the
practice of establishing a short-term test
and only checking its 'sensitivity" with
chemically unrelated carcinogens. For
example a positive response given by
2AAF, although acting as a test system
control, would not automatically guard
against potentially carcinogenic analogues
of safrole from passing undetected.
One solution to this problem would be
for those engaged in the routine testing
ofchemicals to gather together a collection
of carcinogenic and non-carcinogenic ana-
logues from as many discrete classes of
chemical carcinogens as possible to act as
chemical-class controls. It should then be
possible to select in advance the most
appropriate short-term test with which to
evaluate a structurally coherent series of
compounds simply by testing the appro-
priate controls in a variety of tests and
choosing the test with the best response
in Table II.
For example, the CCCP formed by
nitrosofolic acid and diphenylnitrosamine
was correctly identified only by the Ames,
cell-transformation anddegranulationtests
(Table IX). The implant test appears to
detect nitrosamines as negative, irrespec-
tive of their carcinogenic or non-carcino-
genic properties. The sebaceous gland test
and the tetrazoliuim-reduction tests have
TABLE IX.
Test compotin(
Nitrosofolic acidi
Diphenylnitrosamniiie
HMPA
Dieth Istillbostrol
Ames' Cell trans- Rabin's
te.st formation test
Subeuta- Sebaceous- Tetra- Aiiimal
ncoons- glaind zoliuim carcino-
implants suppression recluction genicity
-1 +
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a response inverse to carcinogenicity.
These latter 3 tests are consequently
unsuitable for the evaluation of the
potential carcinogenicity of nitrosamines,
and it would clearly be wrong to draw
conclusions from any positive or negative
results given by these 3 tests for a nitro-
samine. In addition, given that the first 3
tests are suitable for the evaluation ofthe
potential carcinogenicity of nitrosamines,
it would be better to choose either of the
first 2 tests rather than the degranulation
test, on the basis of the overall reliability
gradings of these tests. Similarly, since
the response of the Ames test to the
carcinogen HMPA (IV) is erratic, the
cell-transformation test has been defined
in advance as the better test with which
to evaluate analogues of HMPA. None of
the 6 tests is suitable to evaluate analogues
of DES. It is currently possible to define
and synthesize about 20 CCCPs from the
various classes of carcinogens. These pairs,
together with a variety of known animal
carcinogens which as yet have no well
defined non-carcinogenic analogues (such
as hydrazine and aflatoxin B1) could be
used to select and monitor the most
responsive test for a particular class of
test compounds and also to critically
compare new or developing short-term
test systems.
It is not always possible to select
appropriate chemical-class controls. When
this situation occurs it should either be
clearly accepted (especially if negative
results occur) or an attempt should be
made to establish ab initio a standard
carcinogen and non-carcinogen for the
new class by means of conventional long-
term animal studies.
"FALSE" RESULTS
False negatives
Negative short-term predictions for an
established animal carcinogen, or a com-
pound ultimately capable of being shown
to be such, could be anticipated to occur
for 2 main reasons. The first may be
because the carcinogenicity of the com-
pound was not assessed via a sensitive
test. Thus, carcinogens which elicit their
effect by a disturbance of a hormonal
mechanism (such as diethylstilboestrol)
or via a solid-state mechanism (such as
asbestos or plastic implants) would not
necessarily be expected to give positive
results in short-term tests. Likewise, a
lack of response by such tests could be
anticipated for purely inorganic carcino-
gens where direct covalent interaction
with DNA is unlikely to occur, and for
compounds whose carcinogenicity results
from continual physico-chemically in-
duced tissue damage and its resultant
repair (for example repeated s.c. injections
of hypertonic solutions or repeated liver
damage from some hepatotoxins). Itis also
not yet clear whether chemicals which are
thought to produce cancer via free-radical
formation will be detected by those tests.
The second area of anticipated failure has
been discussed aboveandelsewhere (Ashby
et al., 1977) and concerns the selection
and optimization of the best test for a
particular class of potential carcinogens.
False positives
Although positive results generated for
animal non-carcinogens appear to offer a
smaller problem, their widespread occur-
rence would make them significant. Again,
there are 2 major potential causes of such
results. The first is that the animal study
is inadequate. For example, a non-
sensitive species may have been selected
for testing or the route of administration
of the compound failed to maximize its
carcinogenic potential. Alternatively the
study may have been terminated too soon
or the pathology of the animals was
inadequate. The latter 2 objections apply
particularly to most of the currently
known "false-positive" results, as they
are often based upon older animal studies,
conducted with protocols which would be
unacceptable by today's standards. There
will, however, remain a nucleus ofgenuine
false-positive predictions due to the gross
simplicity of any test when compared to
whole animal absorption, distribution,
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metabolism (both detoxification and carci-
nogenic activation) and excretion of
compounds. Further such tests do not
allowforthenormalprotective mechanisms
which operate in vivo, such as DNA
repair, immunological surveillance and
death prior to overt cancer induction. In
particular, the selection of dose levels for
an animal study may be critical to the
outcome of the experiment, depending
upon whether or not such protective
mechanisms are maintained intact during
the study.
Finally it is too early to discount the
possibility that an otherwise reliable test
may respond positively to chemicals of a
particular type due to specific factors
which are not associated with carcino-
genicity.
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